PPT-Analysis of Sustained MRD-Negativity and Progression-Free Survival of Isa-KRd in High-Risk

ProgressionFree Survival of Isa KRd in HighRisk Newly Diagnosed Multiple Myeloma Additional Data From Planned Interim Analysis of the GMMGCONCEPT Trial Lisa B Leypoldt Diana Tichy Britta . Dr Matthew Jenner. Consultant Haematologist. Southampton General Hospital . UK Myeloma Forum Autumn Day. 12 November 2014. Introduction. Why define high risk myeloma?. 3. Patient expectations. Outcomes vary widely between different patients. NICE Guideline. Published Feb 2016. Adults with myeloma (and plasma cell leukaemia). Excluded:. Monoclonal . gammopathy. of uncertain significance (MGUS). Amyloidosis. Solitary . plasmacytomas. Included:. CV . on the University of Zakho Website . Vaman . M. . Haji. Staff Portal. StaffPortal.uoz.edu.krd . You either go to here. www.uoz.edu.krd. Or . UoZ. Website then Services. Click Login . Enter your . Study of . clinocopathological. profile and chromosomal abnormalities by FISH in newly diagnosed multiple myeloma. Investigator – Dr. . Sukanya. S K.. Guide: Dr. . Shivani. . Vignesh. .. Co-guide- Dr . Program Goals. Defining Multiple Myeloma. Case 1. Diagnostic Criteria. Multiple Myeloma Requiring Therapy. Cytogenetic Risk Features. Case 1 (cont). Newly Diagnosed Multiple Myeloma. NCCN. ®. . Therapy for Transplant-Eligible Patients. Smoldering Myeloma: To Treat or not to Treat Ruben Niesvizky MD Myeloma Center Myelomacenter.org run9001@med.cornell.edu CASE A 47-year-old man is diagnosed with smoldering multiple myeloma . He has Pritesh Patel, MD. OVErview. Disease overview. How I approach initial treatment. Treatment considerations at relapse. ≈96,000. MM patients. How many people are affected by myeloma?. National Cancer Institute Survival Epidemiology and End Results Program SEER Cancer Statistics Review 1975-2012. Available at . Roger Owen. St James’s Institute of Oncology. Leeds. “Minimal Resistant Disease”: challenges to consider.. Genomic heterogeneity. Spatial heterogeneity. Lahuerta. . et al. , J . Clin. . Oncol. Vi Dao, MD, FRCPC. vdao@cancercare.mb.ca. Presenter Disclosure. Faculty: Vi Dao. Relationships with commercial interests: none. Mitigating Potential Bias. Not Applicable. Learning Objectives. Distinguish MGUS from multiple myeloma. Ibr+Ven. ) Versus Chlorambucil Plus Obinutuzumab (. Clb+O. ) for First-Line Treatment of CLL in Elderly or Unfit Patients: The GLOW Study. Talha Munir. ,. 1. Carol Moreno,. 2. Carolyn Owen,. 3. George Follows,. MULTIPLE MYELOMA AND LABORATORY VALUES Benjamin Parsons, DO bmparson@gundersenhealth.org Gundersen Health System Center for Cancer and Blood Disorders La Crosse, WI Multiple Myeloma is a cancer of Myeloma Symposium 9/29/2018. Aric Hall, MD – Assistant Professor – UW School of Medicine & Public Health. Disclosures. I have no significant conflicts of interest to disclose. . I have no financial relationship with any institution profiting from pharmaceutical sales, diagnostic testing, or any type of medical technology. . Myelom. Heinz . Gisslinger. Medizinische Universität Wien. . Medizinische . Universität Wien. Die häufigsten Tumorlokalisationen nach Geschlecht (2014). . 20.361 Männer = 100% 18.547 Frauen = 100%. IMW | SOHO | SOHO Italy. Dr.. Claudio . Cerchione. , MD, PhD. Istituto. . Scientifico. Romagnolo per lo Studio e la . Cura. . dei. . Tumori. IRCCS. Meldola. , Italy. HIGHLIGHTS FROM LYMPHOMA & MYELOMA CONNECT.